![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) — Cerevance, a non-public, clinical-stage drug discovery and improvement firm centered on central nervous system (CNS) ailments, at this time introduced the appointment of Ottavio V. Vitolo, M.D. as chief medical officer. Dr. Vitolo brings greater than 20 years of expertise in neuroscience analysis and drug improvement. He joins Cerevance to steer the worldwide medical improvement and regulatory operations.
“We are thrilled to welcome Ottavio whose expertise will help advance our broad portfolio of innovative treatments for neurodegenerative diseases,” mentioned Craig Thompson, chief government officer of Cerevance. “His diverse and extensive experience in translational and clinical research will be an invaluable asset as we strategically advance our pipeline into and through the clinic.”
Dr. Vitolo most just lately served as chief medical officer and world head of R&D at Alcyone Therapeutics. Prior to this place, Dr. Vitolo served as senior vice chairman, head of R&D and chief medical officer at Relmada Therapeutics Inc. While at Relmada, he critically contributed to the corporate’s progress and technique, together with main the profitable initiation and completion of dextromethadone medical research.
Earlier in his profession, Dr. Vitolo was vice chairman of medical improvement at Homology Medicines and held positions of accelerating duties at Pfizer, together with senior director and head of neuromuscular medical analysis, analysis challenge lead, world medical lead and medical director within the neuroscience analysis unit.
Dr. Vitolo is a skilled and practising neuropsychiatrist. After receiving his medical diploma from the University of Rome La Sapienza, he accomplished his psychiatry residency at Washington University in St. Louis and accomplished a fellowship in behavioral neurology and neuropsychiatry at Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Vitolo additionally has a Master of Medical Sciences diploma from Harvard Medical School.
Dr. Vitolo said, “I am delighted to join Cerevance at such a pivotal time in the company’s history. The potential of the NETSseq target discovery platform combined with the broad pipeline creates a tremendous opportunity to bring several novel and potentially transformative therapies to patients.”
About Cerevance
Cerevance is a non-public pharmaceutical firm whose lead therapeutic, CVN424, a first-in-class, oral, non-dopaminergic compound performing on a novel goal (GPR6), just lately demonstrated important and clinically significant efficacy in a 135-patient Phase 2 examine in sufferers with Parkinson’s illness. The firm makes use of its proprietary NETSseq expertise platform to extremely selectively determine novel goal proteins which might be both over- or under-expressed in diseased brains. Partnering with over 20 mind banks and evaluating greater than 11,000 human autopsy mind tissue samples, Cerevance is advancing a sturdy pipeline of focused remedies for sufferers with neurodegenerative ailments, together with Parkinson’s illness and Alzheimer’s illness. For further info, please go to www.cerevance.com.
Contacts
Cerevance:
Johnna Simoes, [email protected]
Media:
Andrew Mielach, [email protected], +1-646-876-5868
